Leerink Partners Lowers Recursion Pharmaceuticals (NASDAQ:RXRX) Price Target to $6.00
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its target price dropped by Leerink Partners from $7.00 to $6.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “market perform” rating on the stock. Leerink Partners’ price objective suggests a potential downside of 20.11% from the stock’s previous close. Other […]
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its target price dropped by Leerink Partners from $7.00 to $6.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “market perform” rating on the stock. Leerink Partners’ price objective suggests a potential downside of 20.11% from the stock’s previous close. Other […]
